A medicine to protect the heart during breast cancer chemotherapy
Part of Cancer, Heart & circulation clinical trials.
This early-phase study tests azeliragon to lower the risk of chemotherapy-related heart damage in women with early-stage breast cancer. Participants get their planned standard chemotherapy, plus the study medicine, and are monitored for safety and heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have stage I–III breast cancer and be scheduled for chemotherapy before or after surgery (adjuvant or neoadjuvant)
- Have not had any prior chemo, radiation, or other cancer treatment for early breast cancer (or any other cancer)
- Be age 18 or older, and generally well enough to do daily activities (performance status 0–2)
- Have blood counts and organ tests that are in acceptable ranges (kidney, liver, and bone marrow)
- Be able to use effective birth control during the study, and not be pregnant or breastfeeding
- Not take certain medicines that strongly interact with the study drug (especially strong CYP2C8 inhibitors)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs for people whose breast cancer has stopped responding to a targeted therapy called T-DXd (Enhertu). The goal is to find out if adding a second drug can help control the cancer better.
This trial tests whether a daily pill called dapagliflozin can help protect the heart from damage caused by doxorubicin chemotherapy in people being treated for early-stage breast cancer. If you are starting doxorubicin and have a healthy heart, this might lower your risk of heart problems later.
This trial tests whether two different diabetes drugs (SGLT-2 inhibitors and DPP-4 inhibitors) can help prevent heart damage that anthracycline chemotherapy can cause in breast cancer patients. You would receive one of the two drugs during your treatment to see if it protects your heart.
This study tests whether a blood pressure pill, telmisartan, can protect the heart during chemotherapy for breast cancer. It may help reduce the risk of heart damage caused by doxorubicin (a common chemo drug).
This trial studies whether giving a low dose of azacitidine before surgery can shrink or control high-risk early breast cancer. It’s meant for adults whose cancer has not yet spread to distant organs.
This study tests whether a natural supplement made from grape polyphenols can help protect the heart from damage caused by certain breast cancer chemotherapy drugs. It aims to see if taking this supplement alongside treatment can reduce the risk of heart problems.
Hear when a new Non-metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.